Archive

Tag: Anticoagulation

The ACTIV-4b Trial: Antithrombotics For Treatment of Outpatient COVID-19

Background: Severely ill patients diagnosed with COVID-19 have an increased risk of cardiovascular complications, especially thromboembolic events (Bikdeli 2020). The overall incidence of developing venous thromboembolism (VTE) is approximately 17% in patients diagnosed with COVID-19, with a significantly higher rate ...

Read More
Thoracic and Respiratory

The HEP-COVID Trial: Therapeutic Anticoagulation in Non-Critically Ill COVID-19 Patients

Background: Patients with COVID-19 are at increased risk from thromboembolic phenomena. Patient-specific factors such as comorbidities and immobility have been linked to thrombosis. Disease-specific factors such as virus-induced endothelial changes and cytokine storm may also be triggers. Furthermore, patients with elevated ...

Read More
Hematology and OncologyInfectious DiseaseThoracic and Respiratory

COVID-19 and Anticoagulation: Full Dose or Prophylactic Dose?

Background: Patients with COVID-19 are at a high risk for the development of venous thromboembolic disease . Alveolar capillary microthrombi appear to be 9x more prevalent in patients with COVID-19 compared to H1N1. As a result, enhanced-dose anticoagulation ...

Read More
Hematology and Oncology

COVID-19 Update: Convalescent Plasma Therapy & Anticoagulation

Background: Medicine by press release has been an unfortunate reality of the COVID-19 pandemic.  This is not the standard many physicians would use for medical decision making, but one many of us have had to face; what do I do ...

Read More
Infectious Disease

REBEL Cast Ep81: COVID-19, Thrombosis, and Anticoagulation

Early reports have shown that COVID-19 is most likely causing a hypercoagulable state, however the prevalence of acute VTE and exactly how to treat it is an evolving area.  Limited data suggest pulmonary microvascular thrombosis may play a role in ...

Read More
Hematology and OncologyInfectious Disease
Showing Slide 1 of 6

Sponsored